AN2 Therapeutics, Inc. SEC filings ANTX
AN2 Therapeutics, Inc. has 384 filings in SEC EDGAR's recent list, going back to Sep 24, 2021. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Sep 14, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 4, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 22, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEF 14A | Proxy statement | Apr 22, 2026 | Apr 22, 2026 |
| EFFECT | Filing | Apr 20, 2026 | — |
| 424B3 | Prospectus | Apr 20, 2026 | — |
| 424B5 | Prospectus supplement | Apr 20, 2026 | — |
| CORRESP | Letter to the SEC | Apr 16, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2026 | — |
| S-3 | Shelf registration | Apr 9, 2026 | — |
| 8-K |
Current report
Other events
|
Apr 9, 2026 | Apr 9, 2026 |
| D | Filing | Mar 25, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Mar 20, 2026 | Mar 19, 2026 |
| S-8 | Employee stock plan registration | Mar 17, 2026 | — |
| 10-K | Annual report | Mar 17, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2026 | Mar 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Mar 10, 2026 | Mar 8, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 29, 2026 | Jan 26, 2026 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K | Current report | Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Unregistered share sale
|
Jun 20, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 11, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 27, 2025 | May 22, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K | Current report | May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 1, 2025 | May 1, 2025 |
| ARS | Annual report to shareholders | Apr 11, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEF 14A | Proxy statement | Apr 10, 2025 | Apr 10, 2025 |
| S-8 | Employee stock plan registration | Mar 25, 2025 | — |
| 10-K | Annual report | Mar 25, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 25, 2025 | Mar 25, 2025 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 5, 2024 | Nov 4, 2024 |
| 8-A12B | Filing | Aug 19, 2024 | — |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Aug 19, 2024 | Aug 15, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Regulation FD disclosure, Other events
|
Aug 8, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2024 | Jun 19, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 10-K/A | Amended annual report | May 14, 2024 | Dec 31, 2023 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 19, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2024 | Jun 19, 2024 |
| S-8 | Employee stock plan registration | Mar 29, 2024 | — |
| 10-K | Annual report | Mar 29, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| 8-K |
Current report
Other events
|
Feb 12, 2024 | Feb 12, 2024 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Other events
|
Sep 13, 2023 | Sep 13, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 8, 2023 | Sep 1, 2023 |
| 424B5 | Prospectus supplement | Aug 16, 2023 | — |
| 8-K |
Current report
Material agreement, Other events
|
Aug 16, 2023 | Aug 15, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2023 | Jun 7, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| ARS | Annual report to shareholders | Apr 26, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | Jun 7, 2023 |
| 424B5 | Prospectus supplement | Apr 14, 2023 | — |
| EFFECT | Filing | Apr 13, 2023 | — |
| CORRESP | Letter to the SEC | Apr 11, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2023 | — |
| S-3 | Shelf registration | Apr 6, 2023 | — |
| S-8 | Employee stock plan registration | Mar 30, 2023 | — |
| 10-K | Annual report | Mar 29, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2023 | Mar 29, 2023 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 6, 2022 | Oct 6, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Other events
|
Jun 29, 2022 | Jun 29, 2022 |
| 10-Q | Quarterly report | May 10, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Officer or director change
|
May 9, 2022 | May 5, 2022 |
| S-8 | Employee stock plan registration | Mar 29, 2022 | — |
| 424B4 | Prospectus | Mar 28, 2022 | — |
| SEC STAFF LETTER | Filing | Mar 24, 2022 | — |
| EFFECT | Filing | Mar 24, 2022 | — |
| S-1MEF | Filing | Mar 24, 2022 | — |
| CERT | Filing | Mar 24, 2022 | — |
| 8-A12B | Filing | Mar 22, 2022 | — |
| CORRESP | Letter to the SEC | Mar 22, 2022 | — |
| CORRESP | Letter to the SEC | Mar 22, 2022 | — |
| S-1/A | Amended registration statement | Mar 21, 2022 | — |
| SEC STAFF LETTER | Filing | Mar 10, 2022 | — |
| S-1 | Registration statement | Mar 4, 2022 | — |
| DRSLTR | Filing | Jan 19, 2022 | — |
| DRS/A | Filing | Jan 19, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 3, 2021 | — |
| DRS/A | Filing | Nov 19, 2021 | — |
| DRSLTR | Filing | Nov 18, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 22, 2021 | — |
| DRS | Filing | Sep 24, 2021 | — |
Showing 110 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1880438
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.